Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2003, Pages 147-151

  Ankerst, Jaro ^a   Persson, Gunnar ^a   Weibull, Eva ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma; Budesonide formoterol; Maintenance; Relief; Tolerability

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; LACTIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; ASTHMA; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INHALER; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOM;

EID: 0038336230     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(03)00004-X     Document Type: Article

References (12)

1. Pocket guide for asthma management. Pocket guide for asthma management. 1998;NIH/NHLBI, Bethesda. Publication number 96-3659B.
2. Tötterman K.J., Huhti L., Sutinen E., Backman R., Pietinalho A., Falck M., et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J. 12:1998;573-579.
3. Malolepszy J., Böszörmény N.G., Selroos O., Larsson P., Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J. 18:2001;928-934.
4. Zetterström O., Buhl R., Mellem H., Perpiñá M., Hedman J., ONeill S., Ekström T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 18:2001;262-268.
5. Lalloo U., Malolepszy J., Kozma D., Krofta K., Ankerst J., Johansen B., Thomson N.C. Low dose Symbicort (budesonide/formoterol) is more effective than double-dose inhaled corticosteroid in mild asthma. Allergy Clin Immunol Int. 12:(Suppl. 2):2000;435.
6. Palmqvist M., Persson G., Lazer L., Rosenborg J., Larsson P., Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 10:1997;2484-2489.
7. ®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 94:2000;607-611.
8. Palmqvist M., Arvidsson P., Beckman O., Peterson S., Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhaler. Pulm Pharmacol Ther. 14:2001;29-34.
9. Bazett H.C. An analysis of the time relations of electrocardiograms. Heart. 7:1920;353-370.
10. Guhan A.R., Cooper S., Oborne J., Lewis S., Bennett J., Tattersfield A.E. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 55:2000;650-656.
11. Widerlöv E., Jostell K.-G., Claesson L., Odlind B., Keisu M., Freyschuss U. Influence of food intake on electrocardiograms of healthy male volunteers. Eur J Clin Pharmacol. 55:1999;619-624.
12. Man C.Y., Kirby S.M., McRae J. Systemic pharmacodynamic effects of salmeterol in the salmeterol/FP combination Diskus™ inhaler. Eur Respir J. 9:(Suppl. 3):1996;164s.